FDA reviews "possible" CV risks with Parkinson's drug Stalevo
This article was originally published in Scrip
Executive Summary
The US FDA has notified healthcare professionals that it is reviewing clinical trial data that suggests that patients taking Orion/Novartis's Parkinson's disease treatment Stalevo (a combination formulation of carbidopa, levodopa and entacapone) may be at a higher risk for cardiovascular events such as myocardial infarction, stroke and death compared with those taking carbidopa/levodopa (sold as the combination product, Sinemet).